Dr. Reddy's Laboratories Limited

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:23:02 2024-04-19 am EDT			5-day change	1st Jan Change
5,943 ^INR	-0.28%		-2.33%	+2.50%

Apr. 19	Dr. Reddy's Labortories Launches Care Plan for IBS Patients	MT
Apr. 18	India's Biocon developing its own version of Wegovy, clinical trial likely next year	RE

Dr Reddy Laboratories : 2Q Net Fell 30%

October 28, 2020 at 04:35 am EDT

By P.R. Venkat

Dr. Reddy's Laboratories Ltd.'s second-quarter net profit fell 30% from a year earlier mainly due to the recognition of deferred tax assets for one of its subsidiaries.

Net profit for the quarter ended September declined to $104 million, while revenue rose marginally by 2% to $666 million, the company said Wednesday.

"During the quarter we saw gradual recovery in the market demand across India, Russia and other markets after low demand in first quarter, although demand is yet to fully recover to pre-Covid levels," the company said.

Write to P.R. Venkat at venkat.pr@wsj.com

(END) Dow Jones Newswires

10-28-20 0434ET

Latest news about Dr. Reddy's Laboratories Limited

Dr. Reddy's Labortories Launches Care Plan for IBS Patients	Apr. 19	MT
India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Apr. 18	MT
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	Apr. 17	MT
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	Apr. 16	MT
Dr. Reddy's Launches Migraine Management Device Nerivio in Germany	Apr. 10	MT
Dr. Reddy's Launches Migraine Management Wearable in Germany	Apr. 10	MT
Asian Equities Traded in the US as American Depositary Receipts Start Week on Strong Note in Monday Trading	Apr. 08	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 05	MT
Dr. Reddy's Laboratories, Bayer Collaborate to Distribute Second Brand of Heart Failure Drug in India	Apr. 05	MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading, End Week Lower	Apr. 05	MT
Bayer and Dr. Reddy's Sign A Marketing and Distribution Agreement for Second Brand of Vericiguat in India	Apr. 05	CI
Asian Equities Traded in the US as American Depositary Receipts Rebound in Early Wednesday Trading	Apr. 03	MT
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts	Apr. 03	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 01	MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Thursday Trading	Mar. 28	MT
Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands	Mar. 28	MT
Dr. Reddy's Laboratories Limited Enters into Exclusive Distribution Partnership with Sanofi Healthcare India Private Limited	Mar. 27	CI
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Mar. 25	MT
Dr. Reddy's Labs Secures Marketing Rights to Treatment for Hypovolemic Shock in India, Nepal	Mar. 22	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
Dr. Reddy's Board to Consider Dividend for Fiscal 2024	Mar. 22	MT
Pharmazz Inc. and Dr. Reddy's Laboratories Limited Enter into A Licensing Agreement to Market Centhaquine as A Resuscitative Agent for Hypovolemic Shock in India	Mar. 22	CI
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	Mar. 20	MT

Chart Dr. Reddy's Laboratories Limited

Duration

Period

More charts

Company Profile

Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q4 2024 Earnings Release

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Dr. Reddy's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5,943 INR

Average target price

6,001 INR

Spread / Average Target

+0.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DR. REDDY'S LABORATORIES LIMITED	+2.50%	11.87B
ELI LILLY AND COMPANY	+24.60%	654B
NOVO NORDISK A/S	+24.08%	552B
JOHNSON & JOHNSON	-5.63%	356B
MERCK & CO., INC.	+15.37%	319B
ABBVIE INC.	+7.38%	295B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	206B
PFIZER, INC.	-9.69%	147B
AMGEN INC.	-6.63%	144B

Other Pharmaceuticals

Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Dr Reddy Laboratories : 2Q Net Fell 30%

EPS Revisions